Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2022
Health Canada authorises first bivalent COVID-19 booster for adults 18 years and older
1 September 2022 - Today, Health Canada authorised an adapted version of the Moderna Spikevax COVID-19 vaccine. ...
Posted by Michael Wonder on 01 Sep 2022
Vabysmo (faricimab injection) receives positive CADTH recommendation for the treatment of neovascular (wet) age-related macular degeneration in adults
1 September 2022 - Provincial jurisdictions will make the final decision on public reimbursement. ...
Posted by Michael Wonder on 31 Aug 2022
Governor Ron DeSantis announces lawsuit against Biden Administration’s reckless delay of Canadian Prescription Drug Importation Program
31 August 2022 - Today, Governor Ron DeSantis announced a lawsuit against the US FDA in response to their unreasonable delay ...
Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
Posted by Michael Wonder on 30 Aug 2022
Yukon woman paid $7,000 for private ketamine treatment, only to learn that the Yukon Government covers it
29 August 2022 - Evelyn Larson visited a private clinic in Saskatoon only to find the Yukon did cover the treatment ...
Posted by Michael Wonder on 23 Aug 2022
Health Canada approves Opdivo (nivolumab) with chemotherapy as neo-adjuvant treatment for adult patients with resectable non-small-cell lung cancer
23 August 2022 - First and only immunotherapy-based treatment for use before surgery for non-small-cell lung cancer in Canada. ...
Posted by Michael Wonder on 20 Aug 2022
Health Canada approves COVID-19 booster dose for kids 5 to 11
19 August 2022 - The 10 mcg dose can be given at least 6 months after primary series is completed. ...
Posted by Michael Wonder on 18 Aug 2022
Canadians seek diabetes medication as replacement for weight loss drug during arrival delays
18 August 2022 - High demand in the United States for a new weight-loss medication has indefinitely delayed its arrival ...
Posted by Michael Wonder on 16 Aug 2022
Otsuka Canada Pharmaceutical announces Health Canada approval of Korsuva (difelikefalin) for the treatment of moderate to severe pruritus associated with chronic kidney disease in adult haemodialysis patients
16 August 2022 - Launch of Korsuva in Canada is expected in the second quarter of 2023. ...
Posted by Michael Wonder on 11 Aug 2022
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
11 August 2022 - First and only approved medicine targeting germline BRCA mutations in high-risk early breast cancer. ...
Posted by Michael Wonder on 09 Aug 2022
Network collaborators announced for CADTH’s post-market drug evaluation network
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
Posted by Michael Wonder on 09 Aug 2022
Paladin Labs announces Health Canada's filing acceptance of cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy
8 August 2022 - Paladin Labs announced today that Health Canada has accepted its new drug submission for cenobamate tablets as ...
Posted by Michael Wonder on 09 Aug 2022
Introducing CADTH’s RWE Guidance Working Group
9 August 2022 - CADTH is pleased to announce the introduction of the Real-World Evidence Guidance Working Group. ...
Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...